Skip to main content
Fig. 8 | Cell & Bioscience

Fig. 8

From: BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation

Fig. 8

Apg and ABT-263 significantly suppress xenograft tumor growth in vivo. Nude mice bearing H1975 xenografts were grouped and treated with vehicle, ABT-263 (100 mg/kg), Apg (25 mg/kg) or combination therapy daily by oral gavage for 15 days. The tumor volume (a) and body weight (d) were monitored every 2–3 days. The data represents mean ± SD (n = 5). *p < 0.05, and **p < 0.01. At the end of the experiment, tumors were harvested and weighed (b, c). e Total protein lysates were prepared, and the expression levels of p-AKT, AKT, p-ERK1/2, ERK1/2, p-FoxO3a, FoxO3a, cleaved caspase 3 and Noxa were examined by Western blotting. β-Actin was detected as an endogenous loading control. Densitometry measurements, normalized to β-actin, are indicated below the corresponding blot

Back to article page